Sumitomo Pharma America, Inc.

Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in critical patient need areas, including oncology, urology, women’s health, rare disease, cell and gene therapies, and CNS. As a Sumitomo Pharma company, SMPA was formed through the consolidation of its U.S. affiliate companies: Sunovion Pharmaceuticals, Inc., Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc., and Enzyvant Therapeutics, Inc.